Physician profile
Srikar Kumar
NPI 1306265384
$818.85
in general payments reported to CMS, 2019-2025
12 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.27 · 2020: $36.43 · 2021: $153 · 2023: $6.16 · 2024: $194 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533 · Education: $55.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.41 |
| Education | $55.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $204.69 | 2024-2025 | |
| Glaxosmithkline, LLC. | $147.91 | 2021-2024 | Benlysta |
| Calliditas Therapeutics US INC. | $67.99 | 2024-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $57.72 | 2021-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $57.65 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $55.69 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $55.00 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $54.52 | 2025 | Farxiga |
| Akebia Therapeutics INC | $45.73 | 2024-2025 | Vafseo |
| Vifor Pharma, INC. | $36.53 | 2020-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $22.66 | 2020 | |
| Opko Pharmaceuticals, LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikar Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.